A Study of DC05F01 in Chinese Patients with Recurrent/Refractory Ovarian Cancer and Other Advanced Solid Tumors

This study is a multicenter, open-label, cohort expansion Phase Ib/IIa trial designed to evaluate the efficacy, safety, and pharmacokinetic (PK) profile of DC05F01 in patients with recurrent/refractory ovarian cancer and other advanced solid tumors.

Trial Details

NCT ID
NCT06873555
Phase
PHASE1 / PHASE2
Sponsor
Heronova Pharmaceuticals
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • DC05F01
Locations (sample)
  • Bengbu, Anhui, China|32.94083,117.36083
  • Changsha, Hunan, China|28.19874,112.97087

Key Eligibility Criteria

  • Voluntarily signed the informed consent form, understanding the study and willing to follow and capable of completing all trial procedures.
  • Aged ≥18 years, regardless of gender.
  • Patients with locally advanced or metastatic disease, including:
  • Cohort 1: Epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer with FIGO stage III-IV, previously treated with platinum-b…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →